Basilea Pharmaceutica (OTCMKTS:BPMUF) Now Covered by Zacks Research

Zacks Research began coverage on shares of Basilea Pharmaceutica (OTCMKTS:BPMUF – Free Report) in a report released on Monday,Zacks reports. The firm issued a hold rating on the stock.

Basilea Pharmaceutica Price Performance

Shares of Basilea Pharmaceutica stock opened at $84.00 on Monday. The company has a quick ratio of 5.97, a current ratio of 6.60 and a debt-to-equity ratio of 0.44. The stock’s fifty day moving average is $77.42 and its 200 day moving average is $70.11. Basilea Pharmaceutica has a one year low of $59.29 and a one year high of $84.00.

Basilea Pharmaceutica Company Profile

(Get Free Report)

Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.

Recommended Stories

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.